

Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

### Inclusion Criteria:

- diagnosis of inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine cancer - able to walk and complete all self care but unable to carry out any work activities; up and about more than 50% of waking hours - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion and exclusion criteria

---

### Exclusion Criteria:

- significant cardiovascular disease such as heart failure - hypertension that isn't controlled by medication - uncontrolled diabetes - history of liver cirrhosis

## Conditions & Interventions

### Conditions:

Cancer

### Keywords:

Clinics and Surgery Center (CSC), Gastric Cancer, Neuroendocrine tumors, Pancreas, Pancreatic Cancer, Stomach Cancer

## More Information

**Description:** The main purpose of this the study is to find out if a new investigational drug RYZ101 more effectively treats your cancer than the standard therapy, and to see if it is safe, tolerable, and to learn the pharmacokinetics (PK).

**Study Contact:** Samantha Schommer - [schom217@umn.edu](mailto:schom217@umn.edu)

**Principal Investigator:** Edward Greeno, M.D.

**Phase:** PHASE3

### IRB

**Number:** STUDY00021459

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.